# Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression

> **NCT01256177** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 361 (actual)

## Conditions studied

- Bipolar Depression

## Interventions

- **DRUG:** Quetiapine Fumarate (SEROQUEL) Extended Release
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01256177
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 361 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256177, "Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01256177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*